NCT06284395

Two Schemes Response in Multiple Myeloma

Bortezomib, Thalidomide, and Dexamethasone Versus Thalidomide and Dexamethasone for Response Rates in Multiple Myeloma Patients: a Retrospective Study

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 83 (estimated)
• Sponsor: Hospital General de Mexico · Other Government
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination.

Detailed description

The most current treatment of multiple myeloma is based on a combination of drugs, including immunomodulators, proteasome inhibitors, etc. The VTD (bortezomib, thalidomide, and dexamethasone) and TD (thalidomide and dexamethasone) regimens are commonly used as a first-line treatment due to limited resources. The study aimed to compare the proportion of favorable responses, survival, and time to the next treatment between two different treatment approaches. The investigators designed a retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination.

Conditions

• Response, Acute Phase
• Survivorship

Interventions

Type	Name	Description
DRUG	Bortezomib	Bortezomib 1.3mg/m2 SC on days 1,4, 8,11 to the TD scheme for a total of 6 treatment cycles (14,15) (VTD)

Timeline

• Start date: 2023-11-20
• Primary completion: 2024-03-20
• Completion: 2024-10-30
• First posted: 2024-02-28
• Last updated: 2024-10-02

Locations

1 site across 1 country: Mexico